Trial Profile
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Acute heart failure
- Focus Therapeutic Use
- Acronyms PRIME-HF
- 28 Feb 2020 This study is terminated (discontinued) as per results published in the American Heart Journal
- 28 Feb 2020 Primary endpoint Proportion of participants taking Ivabradine at 180 days has been met as per results published in the American Heart Journal
- 28 Feb 2020 Results published in the American Heart Journal